Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma

Scandinavian Journal of Gastroenterology

Volumn 34, Issue 10, 1999, Pages 1033-1041

  Kuriyama, Shigeki ^a   Mitoro, A ^a   Yamazaki, M ^a   Tsujinoue, H ^a   Nakatani, T ^a   Akahane, T ^a   Toyokawa, Y ^a   Kojima, H ^a   Okamoto, S ^a   Fukui, H ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bystander effect; Cytosine deaminase; Gene therapy; Hepatocellular carcinoma; Herpes simplex virus thymidine kinase; Immune response; In vivo; Tumor immunity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; PRODRUG; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GENE; CELL CONTACT; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RETROVIRUS; SUICIDE GENE; TUMOR IMMUNITY; VIRUS GENE;

ANIMALS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CYTOSINE DEAMINASE; ESCHERICHIA COLI; FEMALE; FLUCYTOSINE; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEOSIDE DEAMINASES; PRODRUGS; SIMPLEXVIRUS; STATISTICS, NONPARAMETRIC; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0032717286     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655299750025156     Document Type: Article

References (46)

1. 1. Colombo M. Hepatocellular carcinoma. J Hepatol 1992;15:225-36.
2. 2. Venook AP, Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994;12:1323-34.
3. 3. Farmer DG, Busuttil RW. The role of multimodal therapy in the treatment of hepatocellular carcinoma. Cancer 1994;73;2669-70.
4. 4. Chen MF, Hwang TL, Jeng LB, Wang CS, Jan YY, Chen SC. Postoperative recurrence of hepatocellular carcinoma: two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg 1994;129:738-42.
5. 5. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
6. 6. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 1995;2:702-9.
7. 7. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-10.
8. 8. Ross G. Gene therapy in the United States: a five-year status report. Hum Gene Ther 1996;7:1781-90.
9. 9. Marcel T, Grausz JD. The TMC worldwide gene therapy enrollment report (June 1996). Hum Gene Ther 1996;7:2025-46.
10. 10. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988;10 Suppl 3:490-4.
11. 11. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a new negative selection system. Proc Natl Acad Sci USA 1992;89:33-7.
12. 12. Bi WL, Parysek LM, Warwick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993:4:725-31.
13. 13. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996;3:85-92.
14. 14. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996;93:1831-5.
15. 15. Huber BE, Austin EA, Richards CA, Davis ST, Good S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase genes: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994;91:8302-6.
16. 16. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995;55:4808-12.
17. 17. Holder JW, Elmore E, Barrett JC. Gap junction function and cancer. Cancer Res 1993;53:3475-85.
18. 18. Hoganson DK, Batra RK, Olsen JC, Boucher RC. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effects in lung adenocarcinoma. Cancer Res 1996;56:1315-23.
19. 19. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res 1998;58:2588-93.
20. 20. Rogers RP, Ge J-Q, Holley-Guthrie E, Hoganson DK, Comstock KE, Olsen JC, et al. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther 1996;7:2235-45.
21. 21. Golumbek PT, Hamzeh FM, Jaffee EM, Levitsky H, Lietman PS, Pardoll DM. Herpes simplex virus-1 thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother 1992;12:224-30.
22. 22. Beck C, Cayeux S, Lupton SD, Dörken B, Blankenstein T. The thymidine kinase/ganciclovir-mediated 'suicide' effect is variable in different tumor cells. Hum Gene Ther 1995;6:1525-30.
23. 23. Zhang L, Wikenheiser KA, Whitsett JA. Limitations of retrovirus-mediated HSV-tk gene transfer to pulmonary adenocarcinoma cells in vitro and in vivo. Hum Gene Ther 1997;8:563-75.
24. 24. Patek PQ, Collins JL, Cohn M. Transformed cell lines susceptible or resistant to in vivo surveillance against tumori-genesis. Nature 1978;276:510-1.
25. 25. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986;6:2895-902.
26. 26. Kuriyama S, Yoshikawa M, Tominaga K, Nakatani T, Sakamoto T, Fukui H, et al. Gene therapy for the treatment of hepatoma by retroviral-mediated gene transfer of the herpes simplex virus thymidine kinase. Int Hepatol Commun 1993;1:253-9.
27. 27. Cao G, Kuriyama S, Du P, Sakamoto T, Yang W, Masui K, et al. Construction of retroviral vectors to induce strong hepatoma cell-specific expression of cytokine genes. J Gastroenterol Hepatol 1996;11:1053-61.
28. 28. Cao G, Kuriyama S, Cui L, Nagao S, Pan X, Toyokawa Y, et al. Analysis of the human carcinoembryonic antigen promoter core region in colorectal carcinoma-selective cytosine deaminase gene therapy. Cancer Gene Ther. In press 1999.
29. 29. Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, et al. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology 1995;22:1838-46.
30. 30. Marquardt DW, Siam J. An algorithm for least square estimation of non-linear parameters. J Soc Indust Appl Math 1963;11:431-41.
31. 31. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal G. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995;6:1053-63.
32. 32. Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996;7:713-20.
33. 33. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81.
34. 34. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield E, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256: 1550-2.
35. 35. Fick J, Barker FG, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of hepatocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995;92:11071-5.
36. 36. Wygoda MR, Wilson M, Davis MA, Trosko JE, Rehemtulla A, Lawrence TS. Protection of HSV-TK-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells: the Good Samaritan effect. Cancer Res 1997;57:1699-703.
37. 37. Kuriyama S, Masui K, Sakamoto T, Nakatani T, Tominaga K, Fukui H, et al. Bacterial cytosine deaminase suicide gene transduction renders hepatocellular carcinoma sensitive to the prodrug 5-fluorocytosine. Int Hepatol Commun 1995;4:72-9.
38. 38. Domin BA, Mahony WB, Zimmerman TP. Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem Pharmacol 1993;46:503-10.
39. 39. Colombo BM, Benedetti S, Ottolenghi S, Mora M, Pollo B, Poli G, et al. The 'bystander effect': association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995;6:763-72.
40. 40. Prisbe EJ, Martin JC, McGee DP, Barker MF, Smee DF, Duke AE, et al. Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1, 3-dihydroxy-2-propoxy) methyl] guanine. J Med Chem 1986;29:671-5.
41. 41. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994;54:6228-34.
42. 42. Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995;154:5302-12.
43. 43. Pavlovic J, Nawrath M, Tu R, Heinicke T, Moelling K. Antitumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras (GI2V). Gene Ther 1996;3:635-43.
44. 44. Kuriyama S, Sakamoto T, Masui K, Nakatani T, Tominaga K, Kikukawa M, et al. Tissue-specific expression of HSV-tk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. Int J Cancer 1997;71: 470-5.
45. 45. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997;71:267-74.
46. 46. Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Sakamoto T, et al. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int J Cancer 1999;81:592-7.